BPC-157 Clinical Evidence Base Remains Thin Despite Advisory Vote and Growing Patient Use

A clinical evidence synthesis presented to the FDA Pharmacy Compounding Advisory Committee in 2026 reviewed all available human trial data on BPC-157. Only five trials were identified, each short in duration and small in sample size, and none provided data of sufficient quality to establish safety or efficacy for any of the indications under consideration — including ulcerative colitis, wound healing, obesity, osteoporosis, and opioid withdrawal.

A 2025 peer-reviewed literature review identified additional limitations in the published base, with the human record consisting primarily of a retrospective study in twelve knee-pain patients and one Phase I trial in healthy volunteers whose results were never submitted for publication. The animal literature, by contrast, is extensive and consistently points to angiogenesis and nitric oxide pathways as central mechanisms, with a 2026 commentary in the journal Pharmaceuticals reiterating these mechanistic themes.

The gap between animal mechanistic plausibility and clinical evidence has become particularly salient as patient adverse-event reports accumulate. Recent reporting documented individuals describing fatigue, anxiety, and persistent muscle twitching after BPC-157 use. These reports have no established causal link but reinforce the need for controlled human data before broader adoption.